Stay updated with breaking news from Pharmacodynamic Effects. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations - -
Company to hold investor event in conjunction with data presentation on November 12, 2023 BOSTON, Sept. 26, 2023 -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new...
SAB highlights results from GLP toxicology study confirming SAB-142's mechanism of action at the 23rd Federation of Clinical Immunology Societies Study shows SAB’s fully-human multi-target... | June 21, 2023
NEWARK, CA / ACCESSWIRE / June 6, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that a late-breaking abstract featuring blinded, randomized withdrawal
21.03.2023 - - CEO Participating on Panel Hosted by Alzheimer’s Drug Discovery Foundation -NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) - Cognition Therapeutics, Inc. (NASDAQ: CGTX) will be presenting results of a proteomic biomarker meta-analysis of ... Seite 1